California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...

Soaring demand for weight-loss drugs, expected to be a $150 billion market by early 2030s, has attracted more investors toward companies tapping into the lucrative market. The debut valued BioAge at ...